The pill formulation of zanubrutinib (Brukinsa; BeOne) is currently permitted for all five indications throughout several hematological cancers.A single reason why the cost tag is so high will be to include the costs of developing and making the drug. The worth paid through the NHS for this one particular-off procedure needs to be established again